Targeting PI3K/AKT/mTOR network for treatment of leukemia

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels

(2015) Daniela Bressanin et al.   Oncotarget

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

(2015) Carolina Simioni et al.   Oncotarget

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

(2014) J Bertacchini et al.   LEUKEMIA

Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches

(2014) Fatemeh Salari et al.   MEDICAL ONCOLOGY

PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia

(2014) Fang-Fang Huang et al.   PLoS One

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

(2014) Francesca Pellicano et al.   STEM CELLS

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

(2014) Saeid Shahrabi et al.   TUMOR BIOLOGY

Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells

(2014) L X T Nguyen et al.   Blood Cancer Journal

MicroRNAs in Cancer

(2013) Gianpiero Di Leva et al.   Annual Review of Pathology-Mechanisms of Disease

Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR

(2013) Carl Sandén et al.   BMC CANCER

Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

(2013) Wei Ding et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110β PI3-kinase and requires blockade of all class 1 PI3K activity

(2013) Chloe Stengel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

(2013) Seiichi Okabe et al.   CANCER BIOLOGY & THERAPY

The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells

(2013) Célia Rosilio et al.   CANCER LETTERS

RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms

(2013) Ralph Fritsch et al.   CELL

The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia

(2013) J-N Gong et al.   CELL DEATH AND DIFFERENTIATION

Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity

(2013) Siddhartha Sen et al.   EXPERIMENTAL HEMATOLOGY

Disruption of the PI3K/AKT/mTOR signaling cascade and induction of apoptosis in HL-60 cells by an essential oil from Monarda citriodora

(2013) Anup Singh Pathania et al.   FOOD AND CHEMICAL TOXICOLOGY

The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts

(2013) Najmaldin Saki et al.   Hematology

Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics

(2013) Naif AlQurashi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Notch1 Receptor Regulates AKT Protein Activation Loop (Thr308) Dephosphorylation through Modulation of the PP2A Phosphatase in Phosphatase and Tensin Homolog (PTEN)-null T-cell Acute Lymphoblastic Leukemia Cells

(2013) Eric C. Hales et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

(2013) L M Neri et al.   LEUKEMIA

Genomic Landscapes and Clonality of De Novo AML

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Tanshinone IIA Induces Autophagic Cell Death via Activation of AMPK and ERK and Inhibition of mTOR and p70 S6K in KBM-5 Leukemia Cells

(2013) Sun-Mi Yun et al.   PHYTOTHERAPY RESEARCH

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

(2013) David B. Rosen et al.   PLoS One

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

(2013) Ellen Weisberg et al.   PLoS One

Metformin Induces Apoptosis through AMPK-Dependent Inhibition of UPR Signaling in ALL Lymphoblasts

(2013) Gilles M. Leclerc et al.   PLoS One

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

(2013) S. A. Kang et al.   SCIENCE

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

(2013) K Airiau et al.   Cell Death & Disease

“Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’

(2013) P Oppezzo et al.   Blood Cancer Journal

Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway

(2012) Y. Li et al.   BLOOD

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

(2012) Z. Zeng et al.   BLOOD

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

(2012) C Shepherd et al.   LEUKEMIA

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line

(2012) Hongyun Xing et al.   LEUKEMIA RESEARCH

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells

(2011) E. Vakana et al.   BLOOD

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia

(2011) Teresa Palomero et al.   CELL CYCLE

The physiology and pathophysiology of rapamycin resistance

(2011) Philip A. Gruppuso et al.   CELL CYCLE

Micro RNAs as a new therapeutic target towards leukaemia signalling

(2011) Megan Y. Murray et al.   CELLULAR SIGNALLING

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

(2011) J. K. Altman et al.   CLINICAL CANCER RESEARCH

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts

(2011) G Fuka et al.   LEUKEMIA

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

(2011) L Willems et al.   LEUKEMIA

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis

(2011) Chong Zhang et al.   LEUKEMIA RESEARCH

MiR-223 Suppresses Cell Proliferation by Targeting IGF-1R

(2011) Cheng You Jia et al.   PLoS One

Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome

(2011) H. Sharat Chandra et al.   Cancer Genetics

AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species

(2010) M. M. Juntilla et al.   BLOOD

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

(2010) A. S. Green et al.   BLOOD

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells

(2010) A. F. Santidrian et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

(2010) T. O'Hare et al.   CLINICAL CANCER RESEARCH

Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept

(2010) P. Valent   CURRENT CANCER DRUG TARGETS

Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line

(2010) Haitao Bai et al.   FEBS LETTERS

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Modulation of Akt and ERK1/2 Pathways by Resveratrol in Chronic Myelogenous Leukemia (CML) Cells Results in the Downregulation of Hsp70

(2010) Soumyajit Banerjee Mustafi et al.   PLoS One

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

(2009) Margaret A. Knowles et al.   CANCER AND METASTASIS REVIEWS

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

(2009) J. Zhuang et al.   HAEMATOLOGICA

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

(2009) N. Chapuis et al.   HAEMATOLOGICA

Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

(2009) W-L Zhao   LEUKEMIA

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

(2008) R. Garzon et al.   BLOOD

Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase γ

(2008) Sebastian Scholl et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Acute lymphoblastic leukaemia

(2008) Ching-Hon Pui et al.   LANCET

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

(2007) P. G. Longo et al.   BLOOD